Edition:
India

Diffusion Pharmaceuticals Inc (DFFN.OQ)

DFFN.OQ on NASDAQ Stock Exchange Capital Market

1.42USD
13 Dec 2017
Change (% chg)

-- (--)
Prev Close
$1.42
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
49,053
52-wk High
$15.50
52-wk Low
$1.28

Chart for

About

Diffusion Pharmaceuticals Inc., formerly RestorGenex Corporation, is a clinical-stage biotechnology company. The Company is focused on developing standard-of-care treatments, including radiation therapy and chemotherapy. The Company's lead product candidate, transcrocetinate sodium, also known as trans sodium crocetinate (TSC)... (more)
No analyst recommendations are available for .

Overall

Beta: -0.71
Market Cap(Mil.): $25.24
Shares Outstanding(Mil.): 14.43
Dividend: --
Yield (%): --

Financials

BRIEF-Diffusion Pharma gets FDA protocol guidance for phase 3 trial with TSC

* Diffusion Pharmaceuticals receives final FDA protocol guidance for phase 3 clinical trial with TSC in patients newly diagnosed with inoperable glioblastoma multiforme

17 Oct 2017

Earnings vs. Estimates